Outpace Bio

Executive Summary

Outpace Bio is a Seattle-based biotechnology company founded in 2021 that leverages artificial intelligence to design novel proteins for cell therapies targeting solid tumors. The company’s platform integrates three core technologies—OUTSMART™, OUTLAST™, and OUTSPACER™—which aim to enhance the potency, persistence, safety, and specificity of engineered cells such as CAR-Ts. By addressing key biological barriers in the tumor microenvironment, Outpace Bio seeks to overcome the limitations that have hindered cell therapy efficacy in solid tumors. The company is privately held and has not disclosed total funding or valuation, but its AI-driven approach positions it at the forefront of protein engineering in immuno-oncology. Outpace Bio’s differentiated platform has the potential to unlock new therapeutic options for patients with solid tumors, a significant unmet need. While the company remains in preclinical stages, its innovative protein design capabilities could attract strategic partnerships and investment. The success of its lead programs will depend on demonstrating preclinical proof-of-concept and advancing toward clinical trials. With a strong scientific foundation and a clear focus on solving tumor microenvironment challenges, Outpace Bio represents a promising, albeit early-stage, opportunity in the cell therapy space.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for First OUTSMART-Programmed CAR-T Therapy70% success
• Q2 2026Presentation of Preclinical Data at ASGCT Annual Meeting90% success
• Q3 2026Series B Funding or Strategic Partnership Announcement60% success